TY - JOUR
T1 - An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma
AU - Cook, Martin G
AU - Massi, Daniela
AU - Szumera-Ciećkiewicz, Anna
AU - Van den Oord, Joost
AU - Blokx, Willeke
AU - van Kempen, Léon C
AU - Balamurugan, Thiagarajah
AU - Bosisio, Francesca
AU - Koljenović, Senada
AU - Portelli, Francesca
AU - van Akkooi, Alexander C J
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/6
Y1 - 2019/6
N2 - The sentinel lymph node (SLN) biopsy is a highly accurate staging procedure and the most important prognostic factor in melanoma patients. The European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group aimed to design an updated evolved SLN protocol for the histopathological workup and reporting. We herein recommend extending the distance between steps according to the short axis dimension of the lymph node and optimise both conventional sectioning and staining procedures including immunohistochemistry. We also provide guidance on the description of the spatial localisation of melanoma deposits in a SLN. The histopathological features to be reported include the following: presence or absence of the metastasis, the intranodal location of the metastasis (subcapsular, parenchymal, combined, extensive confluent and extensive multifocal), the number of the metastatic deposits (1, 2-5, 6-10, 11-20 and >20), the maximum dimension of the largest metastasis (indicating its site) and the presence of extracapsular extension and of naevus cells. This updated EORTC protocol is expected to clarify and simplify the existing procedures, ensuring a reasonable workload for the laboratory and for the pathologists resulting in cost saving with no loss, and possible increase, in accuracy.
AB - The sentinel lymph node (SLN) biopsy is a highly accurate staging procedure and the most important prognostic factor in melanoma patients. The European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group aimed to design an updated evolved SLN protocol for the histopathological workup and reporting. We herein recommend extending the distance between steps according to the short axis dimension of the lymph node and optimise both conventional sectioning and staining procedures including immunohistochemistry. We also provide guidance on the description of the spatial localisation of melanoma deposits in a SLN. The histopathological features to be reported include the following: presence or absence of the metastasis, the intranodal location of the metastasis (subcapsular, parenchymal, combined, extensive confluent and extensive multifocal), the number of the metastatic deposits (1, 2-5, 6-10, 11-20 and >20), the maximum dimension of the largest metastasis (indicating its site) and the presence of extracapsular extension and of naevus cells. This updated EORTC protocol is expected to clarify and simplify the existing procedures, ensuring a reasonable workload for the laboratory and for the pathologists resulting in cost saving with no loss, and possible increase, in accuracy.
KW - Immunohistochemistry
KW - Melanoma
KW - Metastasis topography
KW - Nodal naevus cells
KW - Pathology protocol
KW - Recommendations
KW - Sectioning
KW - Sentinel lymph node
KW - Tumour burden
UR - https://www.scopus.com/pages/publications/85064450121
U2 - 10.1016/j.ejca.2019.03.010
DO - 10.1016/j.ejca.2019.03.010
M3 - Article
C2 - 31005015
SN - 0959-8049
VL - 114
SP - 1
EP - 7
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -